Depressive symptoms and non-adherence to treatable cardiovascular risk factors' medications in the CONSTANCES cohort.


Journal

European heart journal. Cardiovascular pharmacotherapy
ISSN: 2055-6845
Titre abrégé: Eur Heart J Cardiovasc Pharmacother
Pays: England
ID NLM: 101669491

Informations de publication

Date de publication:
23 07 2021
Historique:
received: 09 08 2020
revised: 28 09 2020
accepted: 14 10 2020
pubmed: 18 11 2020
medline: 31 3 2022
entrez: 17 11 2020
Statut: ppublish

Résumé

Depression is associated with increased risk of cardiovascular disease (CVD) and the role of poor medical adherence is mostly unknown. We studied the association between depressive symptoms and non-adherence to medications targeting treatable cardiovascular risk factors in the CONSTANCES population-based French cohort. We used CONSTANCES data linked to the French national healthcare database to study the prospective association between depressive symptoms (assessed at inclusion with the Center for Epidemiological Studies Depression scale) and non-adherence to medications (less than 80% of trimesters with at least one drug dispensed) treating type 2 diabetes, hypertension, and dyslipidaemia over 36 months of follow-up. Binary logistic regression models were adjusted for socio-demographics, body mass index, and personal history of CVD at inclusion. Among 4998 individuals with hypertension, 793 with diabetes, and 3692 with dyslipidaemia at baseline, respectively 13.1% vs. 11.5%, 10.5% vs. 5.8%, and 29.0% vs. 27.1% of those depressed vs. those non-depressed were non-adherent over the first 18 months of follow-up (15.9% vs. 13.6%, 11.1% vs. 7.4%, and 34.8% vs. 36.6% between 19 and 36 months). Adjusting for all covariates, depressive symptoms were neither associated with non-adherence to medications for hypertension, diabetes, and dyslipidaemia over the first 18 months of follow-up, nor afterwards. Depressive symptoms were only associated with non-adherence to anti-diabetic medications between the first 3-6 months of follow-up. Non-adherence to medications targeting treatable cardiovascular risk factors is unlikely to explain much of the association between depressive symptoms and CVD at a population level. Clinicians are urged to search for and treat depression in individuals with diabetes to foster medications adherence.

Identifiants

pubmed: 33200205
pii: 5942099
doi: 10.1093/ehjcvp/pvaa124
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

280-286

Informations de copyright

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

Auteurs

Nadine Hamieh (N)

Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, IPLESP, Équipe de Recherche en Épidémiologie Sociale, Paris F75012, France.

Sofiane Kab (S)

INSERM, Population-based Epidemiological Cohorts Unit, UMS 011, Villejuif, France.

Marie Zins (M)

INSERM, Population-based Epidemiological Cohorts Unit, UMS 011, Villejuif, France.
Université de Paris, Faculty of Health, School of Medicine, Paris, France.

Jacques Blacher (J)

Université de Paris, Faculty of Health, School of Medicine, Paris, France.
AP-HP, Centre-Université de Paris, Hôtel-Dieu Hospital, Hypertension and Cardiovascular Prevention Unit, Paris, France.

Pierre Meneton (P)

INSERM U1142 LIMICS, UMRS 1142, Sorbonne Universities, UPMC University of Paris 06, University of Paris 13, Paris, France.

Jean-Philippe Empana (JP)

Université de Paris, INSERM U970, Paris Cardiovascular Research Centre (PARCC), Team 4 Integrative Epidemiology of Cardiovascular Diseases, Paris, France.

Nicolas Hoertel (N)

Université de Paris, Faculty of Health, School of Medicine, Paris, France.
Université de Paris, INSERM, Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR_S1266, Paris, France.
AP-HP, Centre-Université de Paris, Hôpital Corentin-Celton, Service de psychiatrie et d'addictologie de l'adulte et du sujet âgé, Issy-les-Moulineaux, France.

Frederic Limosin (F)

Université de Paris, Faculty of Health, School of Medicine, Paris, France.
Université de Paris, INSERM, Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR_S1266, Paris, France.
AP-HP, Centre-Université de Paris, Hôpital Corentin-Celton, Service de psychiatrie et d'addictologie de l'adulte et du sujet âgé, Issy-les-Moulineaux, France.

Marcel Goldberg (M)

INSERM, Population-based Epidemiological Cohorts Unit, UMS 011, Villejuif, France.
Université de Paris, Faculty of Health, School of Medicine, Paris, France.

Maria Melchior (M)

Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, IPLESP, Équipe de Recherche en Épidémiologie Sociale, Paris F75012, France.

Cedric Lemogne (C)

Université de Paris, Faculty of Health, School of Medicine, Paris, France.
Université de Paris, INSERM, Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR_S1266, Paris, France.
AP-HP, Centre-Université de Paris, Hôpital Hôtel-Dieu, Service de psychiatrie de l'adulte, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH